Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Globe Newswire•23/07/2026•07:30 ET
0
Whiz Insights
* First global approval of a once-daily, orally administered, Complement Factor B inhibitor
* Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH
Get started
Create a free account to read the full story.